SynthesisCNS neuroscience & therapeutics2019
Available and future treatments for atypical parkinsonism. A systematic review.
Synthesis in CNS neuroscience & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Available and future treatments for atypical parkinsonism. A systematic review.CNS neuroscience & therapeutics · 2019Pooled it
- Clinical telemonitoring and telerehabilitation of cognition in rare neurological diseases: a scoping review.Journal of neurology · 2026Article
- Pilot randomised controlled trial of a novel form of exercise on parkinsonism symptoms.BMJ neurology open · 2026Article
- Determinants of care partner burden in atypical Parkinsonian syndromes: A retrospective, multi-center analysis.Clinical parkinsonism & related disorders · 2024Article
- Sentence completion in progressive supranuclear palsy following transcranial direct current stimulation.NPJ Parkinson's disease · 2023Article
- Neurological update: the palliative care landscape for atypical parkinsonian syndromes.Journal of neurology · 2023Article
- Review
- Predict initial subthalamic nucleus stimulation outcome in Parkinson's disease with brain morphology.CNS neuroscience & therapeutics · 2022Article
- Effects of a probiotic suspension Symprove™ on a rat early-stage Parkinson's disease model.Frontiers in aging neuroscience · 2022Article
- Short- and Long-Term Effect of Parkinson's Disease Multimodal Complex Treatment.Brain sciences · 2021Article
- Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.Nature reviews. Neurology · 2021Review
- The Metabolomic Approach Reveals the Alteration in Human Serum and Cerebrospinal Fluid Composition in Parkinson's Disease Patients.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Parkinson-like early autonomic dysfunction induced by vagal application of DOPAL in rats.CNS neuroscience & therapeutics · 2021Article
- Asymmetric, multifocal musculoskeletal pain preceding the onset of progressive supranuclear palsy: A case report.CNS neuroscience & therapeutics · 2021Article
- MDS criteria for the diagnosis of progressive supranuclear palsy overemphasize Richardson syndrome.Annals of clinical and translational neurology · 2020Article
- Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions.Translational neurodegeneration · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsSuccess in treating patients with atypical parkinsonian syndromes, namely progressive supranuclear palsy (PSP), cortico-basal degeneration (CBD), multiple system atrophy (MSA), Parkinson's disease with dementia (PDD), and Lewy body dementia with (LBD), remains exceedingly low. The present work overviews the most influential research literature collected on MEDLINE, ISI Web of Science, Cochrane Library, and Scopus for available treatment in atypical parkinsonisms without time restriction. DISCUSSION: Transdermal rotigotine, autologous mesenchymal stem cells, tideglusib, and coenzyme Q10 along with donepezil, rivastigmine, memantine, and the deep brain stimulation have shown some benefits in alleviating symptoms in APS. Moreover, many new clinical trials are ongoing testing microtubule stabilizer, antitau monoclonal antibody, tau acetylation inhibition, cell replacement, selective serotonin reuptake inhibitor, active immunization, inhibition of toxic α-synuclein oligomers formation, and inhibition of microglia.
conclusionA detailed knowledge of the pathological mechanism underlying the disorders is needed, and disease-modifying therapies are required to offer better therapeutic options to physician and caregivers of APS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.